Shire Canada Inc.
Records under this name other than patents Shire Canada Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,955,835 | Stereoselective Process for the Production of Dioxolane Nucleoside Analogues Formerly held Term ended Term ended Jun 13, 2025 · High confidence | Term ended | Term ended Jun 13, 2025 | High confidence |
| US 7,465,465 | Pharmaceutical Formulation Comprising Lanthanum Compounds Formerly held Term ended Term ended Oct 9, 2024 · High confidence | Term ended | Term ended Oct 9, 2024 | High confidence |
| US 6,645,972 | Methods of Treating Leukemia Formerly held Term ended Term ended Nov 4, 2022 · High confidence | Term ended | Term ended Nov 4, 2022 | High confidence |
| US 6,800,639 | Pharmaceutical Combination for the Treatment of Cancer Formerly held Term ended Term ended Mar 25, 2022 · High confidence | Term ended | Term ended Mar 25, 2022 | High confidence |
| US 8,399,655 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof Lapsed on the fee record Ended Mar 19, 2021 · USPTO record | Lapsed on the fee record | Ended Mar 19, 2021 | USPTO record |
| US 6,630,480 | Methods of treating leukemia Formerly held Term ended Term ended Mar 28, 2020 · USPTO record | Term ended | Term ended Mar 28, 2020 | USPTO record |
| US 6,747,036 | Methods of Treating Leukemia Formerly held Term ended Term ended Mar 28, 2020 · Medium confidence | Term ended | Term ended Mar 28, 2020 | Medium confidence |
| US 7,968,703 | Process and Methods for the Preparation of Optically Active CIS-2-Hydroxymethyl-4- (CYTOSIN-1'-YL) -1,3-Oxathiolane or Pharmaceutically Acceptable Salts Thereof Lapsed on the fee record Ended Jun 28, 2019 · High confidence | Lapsed on the fee record | Ended Jun 28, 2019 | High confidence |
| US 6,180,639 | 1,3-oxathiolane nucleoside analogues Term ended Term ended Jan 30, 2018 · USPTO record | Term ended | Term ended Jan 30, 2018 | USPTO record |
| US 5,348,946 | Heteroanthracycline antitumor analogs Term ended Term ended no later than Sep 20, 2014 · Low confidence | Term ended | Term ended no later than Sep 20, 2014 | Low confidence |